Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

April 01, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

April 01, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer

March 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

March 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer

March 23, 2022

From Merck & Co., Inc.

Via Business Wire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation

March 21, 2022

From Merck & Co., Inc.

Via Business Wire

Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT

March 22, 2022

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

March 17, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial

March 16, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility

March 15, 2022

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

February 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Shares Environmental, Social & Governance Priorities and Strategy

February 23, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces New Leadership for Human Health Business

February 16, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status

February 14, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities

February 14, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

From Merck & Co., Inc.

Via Business Wire

Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine

February 09, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States

February 08, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Guggenheim Oncology Conference 2022

February 04, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results

February 03, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

January 28, 2022

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

January 27, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Second-Quarter 2022 Dividend

January 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Provides U.S. and Japan Regulatory Update for Gefapixant

January 24, 2022

From Merck & Co., Inc.

Via Business Wire

Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine

January 20, 2022

From Merck & Co., Inc.

Via Business Wire

Frank Clyburn to Leave Merck

January 20, 2022

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib

January 18, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

January 18, 2022

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

January 10, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3

January 07, 2022

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Merck & Co., Inc.

Starting at /week.